These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
Despite strong earnings, downgrades and lowered price targets indicate caution among analysts. Historical trends show that downgrades often lead to short-term price declines.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Despite strong earnings, downgrades and lowered price targets indicate caution among analysts. Historical trends show that downgrades often lead to short-term price declines.
What happened, with direct paths to the underlying reporting
HAE reported Q1 earnings of $1.10, beating estimates. Quarterly sales reached $321.394 million, exceeding expectations. FY2026 EPS guidance reaffirmed between $4.70 and $5.00. JP Morgan downgraded HAE from Overweight to Neutral. Other analysts maintained rating but lowered price targets.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.